Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy

Takashi Inozume, Tomonori Yaguchi, Ryo Ariyasu, Yosuke Togashi, Takehiro Ohnuma, Akiko Honobe, Hiroyoshi Nishikawa, Yutaka Kawakami, Tatsuyoshi Kawamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.

Original languageEnglish
JournalJournal of Investigative Dermatology
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Lymphocytes
Major Histocompatibility Complex
Tumors
Melanoma
Neoplasms
Therapeutics
Cells
Genes
Immunotherapy
Tissue
Macrophages
Recurrence
Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy. / Inozume, Takashi; Yaguchi, Tomonori; Ariyasu, Ryo; Togashi, Yosuke; Ohnuma, Takehiro; Honobe, Akiko; Nishikawa, Hiroyoshi; Kawakami, Yutaka; Kawamura, Tatsuyoshi.

In: Journal of Investigative Dermatology, 01.01.2019.

Research output: Contribution to journalArticle

Inozume, Takashi ; Yaguchi, Tomonori ; Ariyasu, Ryo ; Togashi, Yosuke ; Ohnuma, Takehiro ; Honobe, Akiko ; Nishikawa, Hiroyoshi ; Kawakami, Yutaka ; Kawamura, Tatsuyoshi. / Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy. In: Journal of Investigative Dermatology. 2019.
@article{331daabc5da9434c814b267b66856dc5,
title = "Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy",
abstract = "Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.",
author = "Takashi Inozume and Tomonori Yaguchi and Ryo Ariyasu and Yosuke Togashi and Takehiro Ohnuma and Akiko Honobe and Hiroyoshi Nishikawa and Yutaka Kawakami and Tatsuyoshi Kawamura",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jid.2019.01.007",
language = "English",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy

AU - Inozume, Takashi

AU - Yaguchi, Tomonori

AU - Ariyasu, Ryo

AU - Togashi, Yosuke

AU - Ohnuma, Takehiro

AU - Honobe, Akiko

AU - Nishikawa, Hiroyoshi

AU - Kawakami, Yutaka

AU - Kawamura, Tatsuyoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.

AB - Major histocompatibility complex class I loss due to the abnormality of β2-microglobulin gene is one of the mechanisms underlying delayed relapses in melanoma patients long after the initial positive responses to anti–PD-1 therapy. However, the tumor-specific reactivity of tumor-infiltrating lymphocytes in tumor lesions that lost major histocompatibility complex class I expression has not been well evaluated. We report the case of a 55-year-old woman with two metastatic melanoma lesions. After a 12-month period of successful tumor suppression by anti–PD-1 antibody therapy, one lesion started to grow again. We resected both lesions and examined the tumor cells and tumor-infiltrating lymphocytes. The shrinking lesion consisted of necrotic tissue and macrophages, and the enlarged lesion consisted of both necrotic tissue and viable tumor cells. The tumor cells completely lost major histocompatibility complex class I expression, but it was restored upon retroviral transduction of the normal β2-microglobulin gene. When we checked the tumor-specific reactivity of tumor-infiltrating lymphocytes derived from the relapsing lesion, we found that these tumor-infiltrating lymphocytes failed to recognize the native tumor cells derived from the lesion, but strongly recognized the major histocompatibility complex class-I–recovered cells by β2-microglobulin transduction. Our report emphasizes the limitations of T-cell–based immunotherapy and highlights the importance of developing alternative strategies for such cases.

UR - http://www.scopus.com/inward/record.url?scp=85062660151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062660151&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2019.01.007

DO - 10.1016/j.jid.2019.01.007

M3 - Article

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

ER -